Japanese industry urges faster insurance listing
This article was originally published in Clinica
The Japanese association representing the in vitro diagnostic industry, the JACR, has accused the government of breaking an agreement to issue reimbursement prices for new products within six months of approval.
You may also be interested in...
Executives at Pfizer and Moderna expressed confidence in their US government partners for initial COVID-19 vaccine distribution and expect pediatric studies to begin before the end of the year. Regeneron will “do the right thing” in pricing its antibody cocktail.
Takeda's acquisition of Shire fueled the company into a top 10 pharma company in the latest Scrip 100 rankings, as other mega-mergers are set to shape the leaderboard in the future.
Indoco’s domestic performance picks up pace as the Indian pharma market sees a “bounce back” after a long COVID-induced slump. The Indian company continues to perform well internationally and grow overall.